Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2006-001577-13Phase 3Completed
Phase 3, randomised trial of mometasone and formoterol in persistent asthma (4 arms), sponsored by Merck & Co. Primary endpoint: FEV1 AUC(0-12 hr) change from baseline to Week 12. Started Sep 2006; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2006-001577-13.